SpyGlass Pharma Inc(SGP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 58.24% | Shs Outstand | 33.5M | Perf Week | 15.2% |
| Market Cap | 1.09B | Forward P/E | - | EPS next Y | -12.63% | Insider Trans | - | Shs Float | 14.0M | Perf Month | 25.04% |
| Enterprise Value | 0.85B | PEG | - | EPS next Q | -0.62 | Inst Own | 40.59% | Short Float | 8.76% | Perf Quarter | 44.3% |
| Income | - | P/S | - | EPS this Y | 86.1% | Inst Trans | 2.86% | Short Ratio | 12.07 | Perf Half Y | 41.72% |
| Sales | - | P/B | 4.68 | EPS next 5Y | 44.6% | ROA | - | Short Interest | 1.22M | Perf YTD | 35.46% |
| Book/sh | 6.95 | P/C | 4.64 | EPS past 3/5Y | -69.04% - | ROE | - | 52W High | -2.87% ($33.47) | Perf Year | - |
| Cash/sh | 7 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 90.56% ($17.06) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 7.92% 6.4% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.75 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 25.06 | EPS Q/Q | 84.99% | Profit Margin | - | RSI (14) | 73.17 | Recom | 1.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 25.06 | Sales Q/Q | - | SMA20 | 22.39% ($26.56) | Beta | - | Target Price | $44 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/6 | SMA50 | 19.93% ($27.11) | Rel Volume | 1.24 | Prev Close | $32.86 |
| Employees | 65 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -14.7% - | SMA200 | 33.67% ($24.32) | Avg Volume(3M) | 0.10M | Price | $32.51 |
| IPO | 2026/2/6 | Option/Short | No/Yes | Trades | 2203 | Volume | 125,374 | Change | -1.07% |
👁️ SpyGlass Pharma (SGP) is a U.S. biotech company developing long-acting drug delivery platforms targeting ophthalmic diseases. Its lead candidate incorporates bimatoprost into an intraocular lens implanted during cataract surgery, enabling long-term drug delivery for patients with glaucoma and elevated intraocular pressure. The company has achieved meaningful results in clinical-stage development and is pursuing a differentiated approach in the field of ophthalmic drug delivery.
Over the past 1 year, on the higher side
3% below its 1-year high.
Traded about as much as usual. That is 124% of its average volume.
Earnings are growing steadily
Earnings are expected to grow by +86.1% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 40.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #153 of 594 in the industry
Based on market cap of $1B.
IMTX#151 Immatics N.V $1B PER - 
JANX#152 Janux Therapeutics Inc $1B PER - SGP#153 SpyGlass Pharma Inc $1B PER - 
INBX#154 Inhibrx Biosciences Inc $1B PER - 
MLTX#155 MoonLake Immunotherapeutics $1B PER - 
FAQ
What kind of company is SGP?
SGP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SGP?
The market cap of SGP is approximately $1.1B, ranking 2,526 within its sector.
What is the 52-week high and low for SGP?
SGP has recorded a 52-week high of $33.47 and a low of $17.06.
